Latest filing published 05 May 2026 for AMGEN INC, €210k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of David M. Reese in Amgen Inc, where the filings describe the role as senior executive. In total, 32 filings cover trades dated from 30 April 2021 to 2 May 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Most recently, on 5 May 2026, the filings show a share grant worth €210k in Amgen Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 32 declarations